MDMAI
Chemical compound
From Wikipedia, the free encyclopedia
MDMAI, also known as 5,6-methylenedioxy-N-methyl-2-aminoindane, is a drug of the 2-aminoindane family developed in the 1990s by a team led by David E. Nichols at Purdue University.[1][2] It acts as a non-neurotoxic serotonin releasing agent (SRA) in animals and is a putative entactogen in humans.[1][2]
- None
- DE: NpSG (Industrial and scientific use only)
- UK: Under Psychoactive Substances Act
| |
 | |
| Clinical data | |
|---|---|
| Other names | 5,6-Methylenedioxy-N-methyl-2-aminoindane; MDMAI |
| Drug class | Serotonin releasing agent; Entactogen |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C11H13NO2 |
| Molar mass | 191.230 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Interactions
History
MDMAI was first described in the scientific literature by David E. Nichols and colleagues in 1990.[1][2]
Chemistry
MDMAI can be thought of as a cyclized analogue of MDMA where the α-methyl group of the alkylamino side chain has been joined back round to the 6-position of the aromatic ring to form an indane ring system. This changes the core structure of the molecule from phenethylamine to 2-aminoindane, and causes the pharmacological properties of the two compounds to be substantially different.[2]